Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures

• Status: Recruiting
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this research study is to find out which type of transversus abdomens plane (TAP) and block (bupivacaine, liposomal bupivacaine or liposomal bupivacaine with re-dosing at 48-60 hours) improves your pain control and lowers your risk of post-operative common side effects of surgery and narcotic pain medications.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Irvine
• Treatments: Bupivacaine

Criteria

Inclusion Criteria

• Age ≥ 18 years old

• Must be undergoing an open gynecologic procedure through a midline vertical incision with a gynecologic oncologist

Exclusion Criteria

• History of chronic pain

• History of opioid dependence

• Suspected or confirmed history of endometriosis

• History of fibromyalgia

• Suspected or confirmed interstitial cystitis or painful bladder syndrome

• History of or current opioid use prior to surgery

• Hypersensitivity to bupivacaine

• Severe hepatic or renal disease